1 Min Read
May 22 (Reuters) - ViaCyte Inc:
* ViaCyte -receives IND allowance from FDA,clearance from Health Canada to commence international clinical trial of pec-direct cell therapy for high-risk type 1 diabetes Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.